Q1 2023 Results

Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Novartis pipeline in Phase 1 Solid tumors Code AAA603 Name 177Lu-NeoB Mechanism Radioligand therapy target GRPR Radioligand therapy target PSMA HIF2A inhibitor Indication(s) Multiple solid tumors Metastatic castration-resistant prostate cancer Renal cell carcinoma AAA817 225 AC-PSMA-617 DFF332 DFF332 IAG933 IAG933 KAZ954 KAZ954 KFA115 KFA115 MGY825 MGY825 NIR178 NIR178 NZV930 NZV930, spartalizumab, NIR178 Immunology Mesothelioma Novel immunomodulatory Agent Ad2AR inhibitor CD73 antagonist Solid tumors Solid tumors NSCLC Cancers Solid tumors Code Name Mechanism MHV370 NG1226 MHV370 NG1226 Neuroscience Code NIO752 Indication(s) Systemic lupus erythematosus Tendinopathy Name NIO752 Mechanism Indication(s) Tau antagonist Alzheimer's disease 35 Investor Relations | Q1 2023 Results Progressive supranuclear palsy Appendix Innovation: Clinical trials Hematology Code Name HDM201 HDM201 (combos) Mechanism MDM2 inhibitor JBH492 JBH492 MBG453 sabatolimab MIK665 MIK665 TIM3 antagonist MCL1 inhibitor PIT565 PIT565 VAY736 ianalumab + ibrutinib BAFF-R inhibitor VOB560 YTB323 VOB560 rapcabtagene autoleucel CD19 CAR-T Cardiovascular Code XXB750 Name XXB750 Mechanism NPR1 agonist Others Code Name Global Health EDI048 EDI048 EYU688 EYU688 KAF156 INE963 ganaplacide INE963 Ophthalmology MHU650 MHU650 Mechanism References Abbreviations INNOVATION 20 lead indications Lead indication Indication(s) Hematological malignancy Hematological malignancy Low risk myelodysplastic syndrome Hematological malignancies B-cell malignancies Hematological malignancy (combo) Diffuse large B-cell lymphoma Cancers Adult ALL Indication(s) Cardiovascular diseases Indication(s) CpPI(4)K inhibitor NS4B inhibitor Non-artemisinin plasmodium falciparum inhibitor Cryptosporidiosis Dengue Malaria prophylaxis Malaria, uncomplicated Diabetic eye diseases NOVARTIS | Reimagining Medicine

View entire presentation